Subtyping of primary aldosteronism by adrenal vein sampling: Effect of acute D2 receptor dopaminergic blockade on adrenal vein cortisol and chromogranin A levels

European Journal of Endocrinology

Volumn 165, Issue 1, 2011, Pages 85-90

  Seccia, Teresa M ^a   Miotto, Diego ^a   De Toni, Renzo ^a   Gallina, Valentina ^a   Vincenzi, Matteo ^a   Pessina, Achille C ^a   Rossi, Gian Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CHROMOGRANIN A; DOPAMINE 2 RECEPTOR; HYDROCORTISONE; METOCLOPRAMIDE; DIAGNOSTIC AGENT;

ADRENAL GLAND; ADRENAL VEIN SAMPLING; ADRENALECTOMY; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD VESSEL PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INFERIOR CAVA VEIN; MALE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RECEPTOR BLOCKING; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; HYPERALDOSTERONISM; MIDDLE AGED; VASCULARIZATION; BLOOD SAMPLING; DOPAMINE RECEPTOR BLOCKING; HYDROCORTISONE RELEASE; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; VENOUS BLOOD;

ADRENAL GLANDS; ADULT; ALDOSTERONE; CHROMOGRANIN A; FEMALE; HUMANS; HYDROCORTISONE; HYPERALDOSTERONISM; MALE; METOCLOPRAMIDE; MIDDLE AGED; RECEPTORS, DOPAMINE D2; VENA CAVA, INFERIOR;

EID: 79959418783     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0246     Document Type: Article

References (24)

1. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F & PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology 2006 48 2293-2300. (doi:10.1016/j.jacc.2006.07.059)
2. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM & Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 3266-3281. (doi:10.1210/jc.2008-0104)
3. Miotto D, De Toni R, Pitter G, Seccia TM, Motta R, Vincenzi M, Feltrin G & Rossi GP. Impact of accessory hepatic veins on adrenal vein sampling for identification of surgically curable primary aldosteronism. Hypertension 2009 54 885-889. (doi:10.1161/HYPERTENSIONAHA.109.134759)
4. Rossi GP, Pitter G, Bernante P, Motta R, Feltrin G & Miotto D. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. Journal of Hypertension 2008 26 989-997. (doi:10.1097/HJH.0b013e3282f9e66a)
5. Stewart PM & Allolio B. Adrenal vein sampling for primary aldosteronism: time for a reality check. Clinical Endocrinology 2010 72 146-148. (doi:10.1111/j.1365-2265.2009.03714.x)
6. Carey RM, Thorner MO & Ortt EM. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine. Journal of Clinical Investigation 1980 66 10-18. (doi:10.1172/JCI109822)
7. Rossi GP, Zanin L, De Toni R, Venturini R, Albertin G, Pavan E & Pessina AC. Dopaminergic regulation of aldosterone secretion in primary aldosteronism: a clinical study. Hypertension Research 1994 17 105-115. (doi:10.1291/hypres.17.105)
8. 2 dopamine receptor and increased protein kinase Cmu phosphorylation in aldosteroneproducing adenoma play roles in aldosterone overproduction. Journal of Clinical Endocrinology and Metabolism 2007 92 1863-1870. (doi:10.1210/jc.2006-2338)
9. Pivonello R, Ferone D, de Herder WW, de Krijger RR, Waaijers M, Mooij DM, van Koetsveld PM, Barreca A, De Caro ML, Lombardi G, Colao A, Lamberts SW & Hofland LJ. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. Journal of Clinical Endocrinology and Metabolism 2004 89 4493-4502. (doi:10.1210/jc.2003-031746)
10. Crivellato E, Nico B & Ribatti D. The chromaffin vesicle: advances in understanding the composition of a versatile, multifunctional secretory organelle. Anatomical Record 2008 291 1587-1602. (doi:10.1002/ar.20763)
11. Barakat MT, Meeran K & Bloom SR. Neuroendocrine tumours. Endocrine-Related Cancer 2004 11 1-18. (doi:10.1677/erc.0.0110001)
12. Montero-Hadjadje M, Ait-Ali D, Turquier V, Guillemot J, Boutahritch M, Magoul R, Malagon MM, Yon L, Vaudry H, & Anouar Y. Chromogranins/ secretogranins and derived peptides: insights from the amphibian model. In Handbook of Biologically Peptides, pp 311-319. Ed. AJ Kastin, 2006.
13. Seccia TM, Miotto D, De Toni R, Maniero C, Vincenzi M, Motta R, Pessina AC & Rossi GP. Chromogranin A measurement for assessing the selectivity of adrenal venous sampling in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2011 96 E825-E829. (doi:10.1210/jc.2010-2172)
14. Rossi GP. Surgically correctable hypertension caused by primary aldosteronism. Best Practice and Research. Clinical Endocrinology and Metabolism 2006 20 385-400. (doi:10.1016/j.beem.2006.07.003)
15. Kamba T & McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. British Journal of Cancer 2007 96 1788-1795. (doi:10.1038/sj.bjc.6603813)
16. Igaz P, Mullner K, Hargitai B, Igaz I, Tombol Z, Racz K & Tulassay Z. Marked chromogranin A elevation in a patient with bilateral adrenal incidentalomas, and its rapid normalization after discontinuation of proton pump inhibitor therapy. Clinical Endocrinology 2007 67 805-806. (doi:10.1111/j.1365- 2265.2007.02957.x)
17. Auchus RJ, Wians FH Jr, Anderson ME, Dolmatch BL, Trimmer CK, Josephs SC, Chan D, Toomay S & Nwariaku FE. What we still do not know about adrenal vein sampling for primary aldosteronism. Hormone and Metabolic Research 2010 42 411-415. (doi:10.1055/s-0030-1252060)
18. Rizzi CA, Mierau J & Ladinsky H. Regulation of plasma aldosterone levels by metoclopramide: a reappraisal of its mechanism from dopaminergic antagonism to serotonergic agonism. Neuropharmacology 1997 36 763-768. (doi:10.1016/S0028-3908(97)00025-7)
19. 4) receptors. Endocrine-Related Cancer 2009 16 281-290. (doi:10.1677/ERC-08-0190)
20. 4 recognition sites in the porcine caudate nucleus by radioligand binding. Neuropharmacology 1994 33 543-549. (doi:10.1016/0028- 3908(94)90085-X)
21. 4 receptors. European Journal of Pharmacology 1995 290 29-36. (doi:10.1016/0922-4106(95)90013-6)
22. 4) receptors in adrenocortical aldosterone-producing adenomas. European Journal of Endocrinology/European Federation of Endocrine Societies 2005 153 939-947. (doi:10.1530/eje.1.02051)
23. Contesse V, Reznik Y, Duparc C, Perraudin V, Vaudry H, Kuhn JM & Lefebvre H. Effects of serotonin and vasopressin on cortisol production from an adrenocortical tumor causing subclinical Cushing's syndrome. Endocrine Research 2002 28 787-791. (doi:10.1081/ERC-120017074)
24. Contesse V, Reznik Y, Louiset E, Duparc C, Cartier D, Sicard F, Laquerriere A, Parmentier F, Kuhn JM, Vaudry H & Lefebvre H. Abnormal sensitivity of cortisol-producing adrenocortical adenomas to serotonin: in vivo and in vitro studies. Journal of Clinical Endocrinology and Metabolism 2005 90 2843-2850. (doi:10.1210/jc.2004-2476)